Trials / Completed
CompletedNCT02174250
The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.
Effect of a Strong Enzyme Inducer, Rifampin, on the Single-Dose Pharmacokinetics of Istradefylline in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to test whether Rifampin affects blood levels of istradefylline in humans. Rifampin could possibly decrease istradefylline levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Istradefylline 40 mg | On Day 1, istradefylline 1 × 40-mg tablet administered alone |
| DRUG | Rifampin 300mg BID + istradefylline 40mg Day 8 only | On Days 1 - 20, rifampin 300mg BID; On Day 8, istradefylline 40 mg administered first with rifampin about 2 hours after istradefylline administration |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2014-08-01
- Completion
- 2014-12-01
- First posted
- 2014-06-25
- Last updated
- 2024-04-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02174250. Inclusion in this directory is not an endorsement.